These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

475 related articles for article (PubMed ID: 10606256)

  • 21. Topoisomerase I inhibitors. An overview of the camptothecin analogs.
    Burris HA; Fields SM
    Hematol Oncol Clin North Am; 1994 Apr; 8(2):333-55. PubMed ID: 8040144
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Irinotecan versus infusional 5-fluorouracil: a phase III study in metastatic colorectal cancer following failure on first-line 5-fluorouracil. V302 Study Group.
    Van Cutsem E; Blijham GH
    Semin Oncol; 1999 Feb; 26(1 Suppl 5):13-20. PubMed ID: 10213010
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Irinotecan: toward clinical end points in drug development.
    Pazdur R
    Oncology (Williston Park); 1998 Aug; 12(8 Suppl 6):13-21. PubMed ID: 9726086
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New drugs in the treatment of colorectal carcinoma.
    Punt CJ
    Cancer; 1998 Aug; 83(4):679-89. PubMed ID: 9708931
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New systemic frontline treatment for metastatic colorectal carcinoma.
    Braun AH; Achterrath W; Wilke H; Vanhoefer U; Harstrick A; Preusser P
    Cancer; 2004 Apr; 100(8):1558-77. PubMed ID: 15073842
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CPT-11: the European clinical development.
    Terret C; Couteau C; Armand JP
    J Infus Chemother; 1996; 6(3):152-7. PubMed ID: 9229329
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New options for the treatment of advanced ovarian cancer.
    Dunton CJ
    Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-2-S5-11. PubMed ID: 9122739
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [DNA topoisomerase inhibitor].
    Sugiura T; Ariyoshi Y
    Gan To Kagaku Ryoho; 1992 Nov; 19(13):2140-5. PubMed ID: 1332623
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Continuing the fight against advanced colorectal cancer: new and future treatment options.
    Bleiberg H
    Anticancer Drugs; 1998 Jan; 9(1):18-28. PubMed ID: 9491788
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Detection of poly(ADP-ribose) polymerase cleavage in response to treatment with topoisomerase I inhibitors: a potential surrogate end point to assess treatment effectiveness.
    Whitacre CM; Zborowska E; Willson JK; Berger NA
    Clin Cancer Res; 1999 Mar; 5(3):665-72. PubMed ID: 10100720
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan.
    Mathijssen RH; Loos WJ; Verweij J; Sparreboom A
    Curr Cancer Drug Targets; 2002 Jun; 2(2):103-23. PubMed ID: 12188913
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CPT-11 (irinotecan) and 5-fluorouracil: a promising combination for therapy of colorectal cancer.
    Saltz L; Shimada Y; Khayat D
    Eur J Cancer; 1996; 32A Suppl 3():S24-31. PubMed ID: 8943662
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Topoisomerase I inhibitors. Review of phase II trials with irinotecan (CPT-11) and topotecan].
    Bonneterre J
    Bull Cancer; 1995 Aug; 82(8):623-8. PubMed ID: 7492818
    [TBL] [Abstract][Full Text] [Related]  

  • 34. DX-8951f, a water-soluble camptothecin analog, exhibits potent antitumor activity against a human lung cancer cell line and its SN-38-resistant variant.
    Joto N; Ishii M; Minami M; Kuga H; Mitsui I; Tohgo A
    Int J Cancer; 1997 Aug; 72(4):680-6. PubMed ID: 9259410
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preclinical and clinical trials of topoisomerase inhibitors.
    Saijo N
    Ann N Y Acad Sci; 2000; 922():92-9. PubMed ID: 11193928
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Update on European adjuvant trials with irinotecan for colorectal cancer.
    Douillard JY; Barbarot V; Bennouna J
    Oncology (Williston Park); 2002 Apr; 16(4 Suppl 3):13-5. PubMed ID: 12014862
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Topoisomerase I inhibitors in the combined-modality therapy of lung cancer.
    Cho LC; Choy H
    Oncology (Williston Park); 2004 Jun; 18(7 Suppl 4):29-39. PubMed ID: 15255165
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins.
    Garcia-Carbonero R; Supko JG
    Clin Cancer Res; 2002 Mar; 8(3):641-61. PubMed ID: 11895891
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Topotecan in advanced colorectal cancer.
    Creemers GJ
    Semin Oncol; 1997 Dec; 24(6 Suppl 20):S20-42-S20-48. PubMed ID: 9425960
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current status of colorectal cancer: CPT-11 (irinotecan), a therapeutic innovation.
    Cunningham D
    Eur J Cancer; 1996; 32A Suppl 3():S1-8. PubMed ID: 8943658
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.